Obstet Gynecol Sci.  2022 Jan;65(1):37-45. 10.5468/ogs.21121.

A comparative study of smica in various body fluids of diagnosed cervical cancer patients and healthy women

• A.Pachani P
• Godbole RR
• Kshersagar J
• Jagdale R
• Gosavi A
• Patil S
• Sharma Rk
• Joshi MG

• KMID: 2524683
• DOI: http://doi.org/10.5468/ogs.21121

Abstract

Objective
Cervical cancer (CC) is a major public health problem in women, and its early detection can help reduce morbidity and mortality. The objective of this study was to compare serum levels of soluble major histocompatibility complex class I-related chain A (sMICA) levels in various body fluids between women diagnosed with CC and healthy women.
Methods
A case-control study was conducted at a tertiary care hospital and a cancer center in Kolhapur, India. Overall, 150 individuals (100 CC patients and 50 healthy women) participated after providing informed written consent. Demographic data, histopathology history, parity, and tumor, node, and metastasis (TNM) staging data were collected. Pap smears, saliva, blood, and urine samples were collected. Pap smears were examined microscopically, and sMICA levels in all samples were determined by enzyme-linked immunoassay (ELISA).
Results
The mean age of women with cervical cancer was 49.86±8.18 years. Squamous cell carcinoma (70%) was the most common histological variant in CC patients. Serum soluble sMICA levels differed significantly with parity and TNM staging (P<0.05). Mean levels of sMICA were significantly different in samples (CC cases vs. healthy patients; saliva: 166.721±108.718 vs. 0.039±0.005 pg/mL; urine: 82.921±45.580 vs. 0.010±0.005 pg/mL; serum: 35.756±10.799 vs. 0.039±0.005 pg/mL, P<0.001).
Conclusion
Levels of sMICA in body fluids can be considered as a diagnostic or prognostic tool to determine disease progression or tumor regression.

Keyword

Body fluids; Neoplastic processes; Parity; Papanicolaou test; Uterine cervical neoplasms

Figure

• 

  Fig. 1 MICA/B expressions in different stages of oral cancer: MICA/B expression is higher in the tumor tissue than in control. (A) Representative IHC for MICA/B in control tissue sections. It did not show expressions of MICA/B (magnification ×40). (B, C) IHC staining of poorly differentiated stage I and II tumor specimens showed intense to moderate staining for MICA/B and (magnification ×40) (D) well differentiated tumor specimens of stage III showed moderate staining (magnification ×40). MICA/B, major histocompatibility complex class I chain-related protein A and B.

• 

  Fig. 2 Pre-treatment and post treatment levels of sMICA in the sera of CC patients and controls. MICA, major histocompatibility complex class I-related chain A; Conc., concentration; adm, admission; Mnt, Month; F/W, follow-up; sMICA, serum levels of soluble major histocompatibility complex class I-related chain A; CC, cervical cancer.

• 

  Fig. 3 (A) sMICA expression in the saliva of cervical cancer patients. (B) sMICA expression in the urine of cervical cancer patients. sMICA, serum levels of soluble major histocompatibility complex class I-related chain A. Conc., concentration. *P <0.0001.

• 

  Fig. 4 (A) Histopathology distribution in healthy women. (B) Histopathology distribution in cervical cancer patients.

Reference

References

1. Srivastava AN, Misra JS, Srivastava S, Das BC, Gupta S. Cervical cancer screening in rural India: status & current concepts. Indian J Med Res. 2018; 148:687–96.

2. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020; 8:e191–203.

3. Bobdey S, Sathwara J, Jain A, Balasubramaniam G. Burden of cervical cancer and role of screening in India. Indian J Med Paediatr Oncol. 2016; 37:278–85.

4. Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013; 5:437–47.

5. Dalal PK, Agarwal M. Postmenopausal syndrome. Indian J Psychiatry. 2015; 57(Suppl 2):S222–32.

6. Catarino R, Petignat P, Dongui G, Vassilakos P. Cervical cancer screening in developing countries at a crossroad: emerging technologies and policy choices. World J Clin Oncol. 2015; 6:281–90.

7. WHO guidelines WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva: World Health Organization;2013.

8. World Health Organization. Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. Geneva: World Health Organization;2014.

9. Mishra GA, Pimple SA, Shastri SS. An overview of prevention and early detection of cervical cancers. Indian J Med Paediatr Oncol. 2011; 32:125–32.

10. Baranwal AK, Mehra NK. Major histocompatibility complex class i chain-related a (MICA) molecules: relevance in solid organ transplantation. Front Immunol. 2017; 8:182.

11. Zhao Y, Chen N, Yu Y, Zhou L, Niu C, Liu Y, et al. Prognostic value of MICA/B in cancers: a systematic review and meta-analysis. Oncotarget. 2017; 8:96384–95.

12. Samuels S, Ferns DM, Meijer D, van Straalen JP, Buist MR, Zijlmans HJ, et al. High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. Tissue Antigens. 2015; 85:476–83.

13. Safaeian M, Solomon D, Castle PE. Cervical cancer prevention--cervical screening: science in evolution. Obstet Gynecol Clin North Am. 2007; 34:739–60. ix

14. Sreedevi A, Javed R, Dinesh A. Epidemiology of cervical cancer with special focus on India. Int J Womens Health. 2015; 7:405–14.

15. Mhaske M, Jawadekar SJ, Saundale SG. Study of association of some risk factors & cervical dysplasia/cancer among rural women. Natl J Community Med. 2011; 2:209–12.

16. Wang W, Zhang F, Hu K, Hou X. Image-guided, intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer. Gynecol Oncol. 2018; 151:444–8.

17. Kashyap N, Krishnan N, Kaur S, Ghai S. Risk factors of cervical cancer: a case-control study. Asia Pac J Oncol Nurs. 2019; 6:308–14.

18. Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G, et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer. 2007; 7:164.

19. Schmiedel D, Mandelboim O. NKG2D ligands-critical targets for cancer immune escape and therapy. Front Immunol. 2018; 9:2040.